Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Axsome Therapeutics (NASDAQ:AXSM) executives provided updates on the company's commercial portfolio and pipeline during a discussion hosted by Leerink Partners biopharma analyst Marc Goodman. Mark Jacobson, the company's COO, and Nick Pizzie, CFO, outlined plans for the antidepressant Auvelity, the early launch of migraine product Symbravo, continued growth for Sunosi, and progress across several development programs. Auvelity: Sales force expansion, coverage gains, and DTC learnings Management said Auvelity finished last year “annualizing just north of $600 million” in revenue, marking its third full year on the market since its 2022 launch. Jacobson said the company has been pleased with performance, including revenue and prescription growth, and emphasized that results were achieved with what he described as a smaller field force that has expanded over time—from 160 representatives initially, to 260 in 2024, and about 300 in 2025. ? Will the Super Mario Movie Make It Showtim
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)GlobeNewswire
- Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth [Yahoo! Finance]Yahoo! Finance
- 2 Under-the-Radar Stocks to Buy and Hold [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- AXSM's page on the SEC website